2025
SJR Q2
JCR Q2 · 4,1
OA
190 matched articles
SCIE
Journal detail
BMC Cancer
- Publisher
- BioMed Central Ltd
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
14712407
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,172
- Quartile Q2
- H-Index 180
- Cites/doc 4,05
- Docs (3y) 4.127
- Cites (3y) 17.143
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 4,1
- 5Y JIF 4,1
- JCI 0,84
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cancer Research Q2
- Genetics Q2
- Oncology Q2
Areas
- Biochemistry, Genetics and Molecular Biology
- Medicine
WoS categories
- Oncology
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 1,172 | 4,1 | 4,1 | 0,84 | Q2 | 180 |
| 2024 | Q2 | Q2 | 1,178 | 3,4 | 3,7 | 0,79 | Q2 | 171 |
| 2023 | Q2 | Q2 | 1,087 | 3,4 | 3,8 | 0,79 | Q2 | 171 |
| 2022 | Q1 | Q2 | 1,137 | 3,8 | 4,3 | 0,78 | Q2 | 171 |
| 2021 | Q2 | Q2 | 1,134 | 4,6 | 4,7 | 0,81 | Q2 | 171 |
| 2020 | Q2 | Q2 | 1,358 | 4,4 | 4,4 | 0,81 | Q2 | 171 |
| 2019 | Q2 | Q3 | 1,186 | 3,1 | 3,4 | 0,79 | Q2 | 171 |
| 2018 | — | Q3 | — | 2,9 | 3,4 | 0,77 | Q2 | — |
| 2017 | Q1 | Q2 | 1,464 | 3,3 | 3,7 | 0,82 | Q2 | 171 |
| 2016 | Q1 | Q2 | 1,488 | 3,3 | 3,6 | — | — | 171 |
| 2015 | Q1 | Q2 | 1,652 | 3,3 | 3,6 | — | — | 171 |
| 2014 | Q1 | Q2 | 1,719 | 3,4 | 3,8 | — | — | 171 |
| 2013 | Q1 | Q2 | 1,694 | 3,3 | 3,6 | — | — | 171 |
| 2012 | Q1 | Q2 | 1,654 | 3,3 | 3,6 | — | — | 171 |
| 2011 | Q1 | Q2 | 1,541 | 3 | 3,3 | — | — | 171 |
| 2010 | Q1 | Q2 | 1,508 | 3,2 | 3,3 | — | — | 171 |
| 2009 | — | Q2 | — | 2,7 | 3 | — | — | — |
| 2008 | — | Q2 | — | 3,1 | 3,2 | — | — | — |
| 2007 | — | Q2 | — | 2,7 | 2,8 | — | — | — |
| 2006 | — | Q3 | — | 2,4 | — | — | — | — |
| 2005 | — | Q3 | — | 2 | — | — | — | — |
| 2004 | — | Q2 | — | 2,3 | — | — | — | — |
| 2003 | — | Q3 | — | 1,7 | — | — | — | — |
| 2002 | — | Q4 | — | 1,1 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | SCIE | Q2 | Q2 | 111/333 |
| 2024 | ONCOLOGY | SCIE | Q2 | Q2 | 118/328 |
| 2023 | ONCOLOGY | SCIE | Q2 | Q2 | 110/322 |
| 2022 | ONCOLOGY | SCIE | Q2 | Q2 | 109/241 |
| 2021 | ONCOLOGY | SCIE | Q2 | Q2 | 109/245 |
| 2020 | ONCOLOGY | SCIE | Q2 | Q2 | 110/242 |
| 2019 | ONCOLOGY | SCIE | Q3 | Q2 | 129/244 |
| 2018 | ONCOLOGY | SCIE | Q3 | Q2 | 121/230 |
| 2017 | ONCOLOGY | SCIE | Q2 | Q2 | 107/223 |
| 2016 | ONCOLOGY | SCIE | Q2 | — | 93/217 |
| 2015 | ONCOLOGY | SCIE | Q2 | — | 85/213 |
| 2014 | ONCOLOGY | SCIE | Q2 | — | 81/211 |
| 2013 | ONCOLOGY | SCIE | Q2 | — | 74/203 |
| 2012 | ONCOLOGY | SCIE | Q2 | — | 73/197 |
| 2011 | ONCOLOGY | SCIE | Q2 | — | 78/196 |
| 2010 | ONCOLOGY | SCIE | Q2 | — | 66/185 |
| 2009 | ONCOLOGY | SCIE | Q2 | — | 72/166 |
| 2008 | ONCOLOGY | SCIE | Q2 | — | 59/143 |
| 2007 | ONCOLOGY | SCIE | Q2 | — | 61/132 |
| 2006 | ONCOLOGY | SCIE | Q3 | — | 67/127 |
| 2005 | ONCOLOGY | SCIE | Q3 | — | 71/123 |
| 2004 | ONCOLOGY | SCIE | Q2 | — | 60/123 |
| 2003 | ONCOLOGY | SCIE | Q3 | — | 81/120 |
| 2002 | ONCOLOGY | SCIE | Q4 | — | 91/114 |